Sangamo Therapeutics Inc (NASDAQ: SGMO) is making a run for the top in the market this morning, and for good reason. The company announced data from a Phase 1/2 trial that it is working on with Pfizer (PFE).
The data release proved to be positive, exciting investors and sending the stock screaming for the top. Today, we’ll talk about:
- The data;
- what we’re seeing from SGMO stock as a result; and
- what we’ll be watching for ahead.
SGMO Stock Climbs On Data Release
As mentioned above, Sangamo Therapeutics is having a great start to the trading session this morning after announcing positive data. The data came by way of a joint press release, issued by both SGMO and PFE.
In the release, the companies announced interim data from the Phase 1/2 Alta study. Through the study, the companies are evaluating investigational SB-525 gene therapy for patients with severe hemophilia A.
In the release, the companies said that the data indicate that SB-525 was generally well tolerated. Moreover, the data show a dose-dependent increase in Factor VIII levels across four dosage cohorts.
Based on the results, the Safety Monitoring Committee (SMC) has recommended cohort expansion at the 3e13 vg/kg dose. The company said that more details will be disclosed in a conference call today, which may be accessed on its website.
In a statement, Edward Conner, MD, CMO at SGMO, had the following to offer:
The interim data from the first eight patients with hemophilia A treated with SB-525 gene therapy in the Alta study are encouraging and demonstrate a dose-dependent relationship, evidence of sustained factor levels, and low variability, both within each patient and within each cohort.
These interim results suggest that SB-525 may be well-tolerated and may prove to have the predictability and sustained treatment effect that can bring clinical benefit in patients with hemophilia A. We need to continue observing how the data mature and how additional patients in the expansion cohort respond to SB-525. We look forward to working with Pfizer to potentially advance SB-525 into a registrational study.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to dig into the market is that the news leads to moves. In the case of Sangamo Therapeutics, the news proved to be overwhelmingly positive.
After all, with dosing of this treatment showing to be safe and well-tolerated, and signs of efficacy starting to emerge already in early stages, the company may be onto something here. So, it’s not surprising to see that investors are excited and the stock is making a run for the top.
As is usually the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (9:21), SGMO is trading at $14.40 per share after a gain of $4.87 per share or 51.10% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on SGMO. In particular, we’re interested in following the continued development of SB-525 as well as the rest of the company’s relatively robust pipeline. Nonetheless, we’ll continue to keep a close eye on the story and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!